Valuation : Amplia Therapeutics Limited

Market Cap 66.73M 48.19M 41.43M 38.98M 35.57M 66.39M 4.57B 462M 179M 2.34B 181M 177M 7.43B P/E 2027 *
-5.65x
P/E 2028 * -18.6x
Enterprise Value 48.83M 35.26M 30.32M 28.52M 26.03M 48.58M 3.34B 338M 131M 1.71B 132M 130M 5.44B EV / Sales 2027 *
-
EV / Sales 2028 * 4.56x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 week-3.70%
Current month-3.70%
1 month-7.14%
3 months+13.04%
6 months+18.18%
Current year-13.33%
1 week 0.12
Extreme 0.125
0.14
1 month 0.12
Extreme 0.125
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 2022-12-04
Director of Finance/CFO - 2021-09-30
Chief Tech/Sci/R&D Officer - 2025-05-11
Director TitleAgeSince
Director/Board Member 70 2015-09-01
Chairman - 2018-05-24
Chairman - 2026-06-29
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/25 Buy

Chairman

336,826 0.0868%
9/8/25 Exercice

Chairman

750,000 0.1933%
9/8/25 Free

Founder

447,000 0.1152%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.70%-21.21%+62.50% 48.17M
+2.02%+1.26%+41.37%+105.18% 67.82B
-0.41%-2.30%+33.53%+78.63% 63.22B
-1.11%+2.78%-14.86%+375.59% 27.58B
-4.92%-3.22%-3.90%-17.87% 26.06B
+0.28%+0.41%+31.28%+15.78% 25.38B
+1.12%+0.84%+24.50%-17.84% 19.89B
+6.04%+7.25%+233.25%+383.12% 17.4B
+0.45%-0.57%-6.36%+527.66% 14.95B
-2.27%+1.37%+53.01%+160.83% 14.62B
Average +0.12%+0.65%+37.06%+167.36% 27.7B
Weighted average by Cap. +0.22%+0.44%+37.67%+140.64%

Financials

2027 *2028 *
Net sales - 9.5M 6.86M 5.9M 5.55M 5.06M 9.45M 650M 65.75M 25.44M 332M 25.76M 25.2M 1.06B
Net income -11.6M -8.38M -7.2M -6.78M -6.18M -11.54M -794M -80.29M -31.06M -406M -31.46M -30.77M -1.29B -4.1M -2.96M -2.55M -2.4M -2.19M -4.08M -281M -28.38M -10.98M -143M -11.12M -10.88M -457M
Net Debt -17.9M -12.93M -11.11M -10.46M -9.54M -17.81M -1.23B -124M -47.93M -626M -48.54M -47.48M -1.99B -23.4M -16.9M -14.53M -13.67M -12.47M -23.28M -1.6B -162M -62.66M -819M -63.46M -62.07M -2.61B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
26-09-08 A$0.1300 0.00% 344,069
26-09-08 A$0.1300 0.00% 1,040,026
26-09-07 A$0.1300 0.00% 32,102
26-09-04 A$0.1300 -3.70% 349,534
26-09-03 A$0.1350 0.00% 143,306
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1300AUD
Average target price
0.4200AUD
Spread / Average Target
+223.08%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!